The DCGI has sought the cancellation of manufacturing licences for obeticholic acid (5mg and 10mg tablets), used to treat primary biliary cholangitis (PBC), following similar actions by the US FDA and the European Medicines Agency.
The DCGI has sought the cancellation of manufacturing licences for obeticholic acid (5mg and 10mg tablets), used to treat primary biliary cholangitis (PBC), following similar actions by the US FDA and the European Medicines Agency.
<iframe src="https://hindustansphere.com/embed/cluster/622c264c9374f1563d0238e581b1ef2d701ea983" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Drug regulator halts obeticholic acid production, orders recall"></iframe>
The DCGI has sought the cancellation of manufacturing licences for obeticholic acid (5mg and 10mg tablets), used to treat primary biliary cholangitis (PBC), following similar actions by the US FDA and the European Medicines Agency.
